Cross-agency comparison: 🇪🇺 EMA leads with 99 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

This comparison suggests that the EMA is currently the most active policy and guidance environment, with MHRA and FDA also generating meaningful but lower-volume output, while Health Canada appears comparatively quieter. Sponsors should consider that the highest-document agencies may be signaling faster-moving expectations, more frequent interpretive shifts, or greater procedural churn, which could make Europe and the UK especially demanding for dossier maintenance and regulatory intelligence. For global filing strategy, this could suggest prioritizing stronger surveillance and earlier cross-functional review for EU/UK programs, while still maintaining disciplined FDA tracking because even lower volume can mask high-impact changes. Resource planning may need to tilt toward regulatory intelligence, CMC, and labeling teams that can absorb more frequent updates, with a more centralized harmonization approach to avoid rework across markets.